

## **DURECT Corporation to Participate in Upcoming Healthcare Conferences**

CUPERTINO, Calif., Nov. 7, 2011 /PRNewswire via COMTEX/ —

DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming healthcare conferences.

(Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

- Jim Brown, President and CEO, will present at the Credit Suisse Health Care Conference in Phoenix, Arizona on Wednesday,
  November 9 at 3:00 p.m. Pacific Time. A live audio webcast of the presentation will be available by accessing
   <a href="http://cc.talkpoint.com/cred001/110911a\_ah/?entity=74\_KGNYQKK">http://cc.talkpoint.com/cred001/110911a\_ah/?entity=74\_KGNYQKK</a>. If you are unable to participate during the live webcast,
  the call will be archived on DURECT's website (<a href="http://www.www.durect.com">www.www.durect.com</a>) under Audio Archive in the "Investor Relations" section.
- Matt Hogan, Chief Financial Officer, will present at the Piper Jaffray Health Care Conference in New York on Tuesday,
  November 29 at 1:00 p.m. Eastern Time. A live audio webcast of the presentation will be available by accessing
  <a href="http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=DRRX&item\_id=4228861">http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=DRRX&item\_id=4228861</a>. If you are unable to participate during the live webcast, the call will be archived on DURECT's website (<a href="https://www.www.durect.com">www.www.durect.com</a>) under Audio Archive in the "Investor Relations" section.

## **About DURECT Corporation**

DURECT is a specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR(TM), ELADUR®, and TRANSDUR®-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit www.www.durect.com.

NOTE: POSIDUR(TM), SABER(TM), ORADUR®, TRANSDUR®, ELADUR(TM) and DURIN® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

SOURCE DURECT Corporation